Crossmark

Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy

Crossref DOI link: https://doi.org/10.1038/s41417-021-00400-x

Published Online: 2021-11-16

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sliheet, Elyssa

Robinson, Molly

Morand, Susan

Choucair, Khalil https://orcid.org/0000-0001-8145-3754
Willoughby, David

Stanbery, Laura

Aaron, Phylicia https://orcid.org/0000-0001-7663-6468
Bognar, Ernest

Nemunaitis, John https://orcid.org/0000-0002-2234-2381
License Information

Text and Data Mining valid from 2021-11-16

Version of Record valid from 2021-11-16
More Information

Article History

Received: 24 June 2021

Revised: 21 September 2021

Accepted: 11 October 2021

First Online: 16 November 2021

Conflict of interest

: The authors declare no competing interests.

Document is current

Any future updates will be listed below